查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1510459

照護端分子診斷市場 - 全球產業規模、佔有率、趨勢、機會和預測，按技術、應用、測試地點、最終用戶、地區和競爭細分，2019-2029F

Point-Of-Care Molecular Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Application, By Test Location, By End User, By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2023 年，全球床邊分子診斷市場估值為 20.7 億美元，到 2029 年，預測期內將以 10.93% 的複合年成長率強勁成長。或附近進行的測試，可在短時間內提供快速且可操作的結果。這些測試利用分子技術來檢測和分析與特定病原體、遺傳變異或疾病生物標記相關的核酸（DNA 或 RNA）。 POC 分子診斷提供快速檢測能力，與傳統的實驗室方法相比，可以在幾分鐘到幾小時內提供結果，而傳統的實驗室方法可能需要幾天才能得出結果。這種快速的周轉時間使醫療保健提供者能夠立即做出治療決策、最佳化患者管理並更有效地實施感染控制措施。 POC 分子診斷利用聚合酶鍊式反應(PCR)、核酸擴增測試(NAAT)、環介導等溫擴增(LAMP) 和基於CRISPR 的檢測等分子技術，以高靈敏度和特異性擴增和檢測目標核酸序列。這些技術能夠檢測與各種疾病和病症相關的病原體、基因突變和生物標記。許多 POC 分子診斷設備被設計為樣本到答案平台，將樣本製備、核酸萃取、擴增和檢測步驟整合到單一儀器或試劑盒中。這些整合平台簡化了測試過程，最大限度地減少了動手時間，並降低了污染風險，使其非常適合在實驗室基礎設施和技術專業知識有限的照護端環境中使用。

市場概況
預測期 2025-2029
2023 年市場規模 20.7億美元
2029 年市場規模 38.7億美元
2024-2029 年複合年成長率 10. 93%
成長最快的細分市場 基於雜交的技術
最大的市場 北美洲

分子生物學、微流體和核酸擴增技術的進步促進了高靈敏度、特異性和方便用戶使用的即時分子診斷設備的開發。這些技術創新擴展了即時檢測的能力，並提高了診斷結果的準確性和可靠性。由於快速獲得診斷服務的需求，尤其是在服務不足或偏遠地區，分散檢測和即時診斷已成為全球趨勢。即時分子診斷消除了對集中實驗室設施的需求，並且可以在患者的床邊、診所、急診室和社區環境中進行測試。照護端分子診斷通常在幾分鐘到幾小時內提供快速測試結果，以便能夠及時做出診斷和治療決策。能夠在照護端立即獲得結果對於管理傳染病、最佳化患者護理和降低疾病傳播風險特別有價值。

主要市場促進因素

分子診斷技術的進步

擴大轉向分散測試

對個人化醫療的需求不斷成長

主要市場挑戰

品質控制和保證

基礎設施和連通性

主要市場趨勢

小型化、便攜化

細分市場洞察

技術洞察

應用洞察

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球照護端分子診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依技術（基於 PCR、基於基因定序、基於雜交、基於微陣列）
    • 按應用（傳染病、腫瘤學、血液學、產前檢測、內分泌學、其他）
    • 按測試地點（OTC、POC）
    • 按最終使用者（分散實驗室、醫院、家庭護理、輔助生活醫療設施、其他）
    • 按地區
    • 按公司分類 (2023)
  • 市場地圖

第 6 章：北美照護端分子診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依技術
    • 按申請
    • 按考試地點
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲照護端分子診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依技術
    • 按申請
    • 按考試地點
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太地區照護端分子診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依技術
    • 按申請
    • 按考試地點
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲照護端分子診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依技術
    • 按申請
    • 按考試地點
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲照護端分子診斷市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依技術
    • 按申請
    • 按考試地點
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 13 章：全球照護端分子診斷市場：SWOT 分析

第14章：競爭格局

  • Siemens Healthineers AG
  • Quidel Corporation
  • F. Hoffman-La Roche Ltd.
  • Danaher Corporation
  • Beckton & Dickinson Company
  • Trinity Biotech plc
  • Thermo Fisher Scientific Inc
  • bioMerieux SA
  • DiaSorin SpA
  • AccuBioTech Co., Ltd

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 23762

Global Point-Of-Care Molecular Diagnostics Market was valued at USD 2.07 billion in 2023 and will see an robust growth in the forecast period at a CAGR of 10.93% through 2029. Point-of-care molecular diagnostics (POC MDx) refers to diagnostic tests that are performed at or near the site of patient care, providing rapid and actionable results within a short timeframe. These tests utilize molecular techniques to detect and analyze nucleic acids (DNA or RNA) associated with specific pathogens, genetic variations, or biomarkers of disease. POC molecular diagnostics offer rapid testing capabilities, providing results in minutes to hours compared to traditional laboratory-based methods, which may take days to deliver results. This rapid turnaround time enables healthcare providers to make immediate treatment decisions, optimize patient management, and implement infection control measures more effectively. POC molecular diagnostics leverage molecular techniques such as polymerase chain reaction (PCR), nucleic acid amplification tests (NAATs), loop-mediated isothermal amplification (LAMP), and CRISPR-based assays to amplify and detect target nucleic acid sequences with high sensitivity and specificity. These techniques enable the detection of pathogens, genetic mutations, and biomarkers associated with various diseases and conditions. Many POC molecular diagnostic devices are designed as sample-to-answer platforms, integrating sample preparation, nucleic acid extraction, amplification, and detection steps into a single instrument or cartridge. These integrated platforms streamline the testing process, minimize hands-on time, and reduce the risk of contamination, making them ideal for use in point-of-care settings with limited laboratory infrastructure and technical expertise.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 2.07 Billion
Market Size 2029USD 3.87 Billion
CAGR 2024-202910. 93%
Fastest Growing SegmentHybridization-Based Technology
Largest MarketNorth America

Advances in molecular biology, microfluidics, and nucleic acid amplification technologies have led to the development of highly sensitive, specific, and user-friendly point-of-care molecular diagnostic devices. These technological innovations expand the capabilities of point-of-care testing and improve the accuracy and reliability of diagnostic results. There is a global trend towards decentralized testing and point-of-care diagnostics, driven by the need for rapid access to diagnostic services, especially in underserved or remote areas. Point-of-care molecular diagnostics eliminates the need for centralized laboratory facilities and enable testing to be performed at the patient's bedside, in clinics, emergency departments, and community settings. Point-of-care molecular diagnostics offer rapid test results, often within minutes to hours, enabling timely diagnosis and treatment decisions. The ability to obtain immediate results at the point of care is particularly valuable for managing infectious diseases, optimizing patient care, and reducing the risk of disease transmission.

Key Market Drivers

Advancements in Molecular Diagnostic Technologies

Next-generation sequencing technologies have transformed genomic analysis by enabling high-throughput sequencing of DNA and RNA molecules. NGS platforms offer unparalleled sequencing depth, resolution, and scalability, facilitating a wide range of applications such as whole-genome sequencing, targeted gene sequencing, transcriptomics, and metagenomics. Digital PCR technologies enable precise quantification of nucleic acid targets by partitioning DNA or RNA samples into thousands of individual reactions. Digital PCR offers superior sensitivity, accuracy, and reproducibility compared to conventional PCR methods, making it ideal for detecting rare mutations, measuring gene expression levels, and quantifying viral load in clinical samples. Isothermal amplification techniques, such as loop-mediated isothermal amplification (LAMP) and recombinase polymerase amplification (RPA), allow rapid amplification of nucleic acids at a constant temperature without the need for thermal cycling. These isothermal amplification methods are well-suited for point-of-care diagnostics, field testing, and resource-limited settings due to their simplicity, speed, and robustness.

CRISPR-based diagnostic technologies leverage the CRISPR-Cas system for nucleic acid detection and gene editing. CRISPR-based diagnostics offer rapid and specific detection of target sequences with high sensitivity and specificity, enabling applications such as pathogen detection, genotyping, and mutation analysis. CRISPR-based diagnostics hold promise for point-of-care testing and precision medicine. Microfluidic-based diagnostic platforms integrate microscale fluid handling and analytical techniques for performing complex molecular assays in miniaturized devices. Microfluidic systems offer advantages such as reduced sample volumes, rapid reaction kinetics, and automation capabilities, making them suitable for point-of-care diagnostics, high-throughput screening, and multiplexed assays.

Biosensors and nanotechnology-based platforms enable label-free detection and quantification of biomolecules with high sensitivity and specificity. Biosensors utilize various transduction mechanisms, including optical, electrochemical, and mechanical signals, for real-time and multiplexed detection of nucleic acids, proteins, and small molecules. Nanotechnology enhances the performance of biosensors by providing nanomaterials with unique properties such as enhanced surface area, biocompatibility, and signal amplification. Artificial intelligence (AI) algorithms and machine learning techniques are increasingly applied to analyze large-scale molecular data generated from diagnostic tests, omics studies, and clinical trials. AI-driven data analytics enable rapid interpretation of complex molecular profiles, prediction of disease outcomes, identification of therapeutic targets, and personalized treatment recommendations, thereby improving patient care and clinical decision-making. This factor will help in the development of the Global Point-Of-Care Molecular Diagnostics Market.

Increasing Shift Towards Decentralized Testing

POC molecular diagnostics offer the advantage of providing rapid test results, often within minutes to hours, compared to traditional laboratory-based testing methods that may take days to deliver results. Timely diagnosis enables healthcare providers to make prompt treatment decisions, leading to improved patient outcomes, particularly in acute conditions such as infectious diseases. POC molecular diagnostics bring diagnostic testing directly to the patient's bedside, clinic, or community setting, eliminating the need for samples to be sent to centralized laboratories. This accessibility and convenience reduce the time and logistical barriers associated with traditional laboratory testing, particularly in remote or resource-limited areas where access to centralized healthcare facilities may be limited. By bypassing the need for sample transportation and centralized laboratory processing, POC molecular diagnostics offer significantly reduced turnaround times for test results. This rapid turnaround time is crucial for managing infectious disease outbreaks, implementing timely interventions, and reducing the risk of disease transmission in healthcare settings and communities.

POC molecular diagnostics empower healthcare providers to make informed treatment decisions at the point of care, based on real-time diagnostic information. This immediate feedback loop enhances clinical decision-making, enables targeted therapy, and supports precision medicine approaches tailored to individual patient needs and disease characteristics. POC molecular diagnostics facilitate rapid screening, diagnosis, and monitoring of infectious diseases, chronic conditions, and therapeutic responses. By providing actionable diagnostic information at the point of care, POC molecular diagnostics enable more proactive and personalized patient management strategies, leading to better disease management and treatment outcomes. POC molecular diagnostics play a critical role in public health preparedness and emergency response efforts, particularly during pandemics, outbreaks, and natural disasters. These diagnostics enable rapid screening, surveillance, and containment of infectious diseases, helping to identify and isolate cases, track transmission chains, and inform public health interventions in real time. This factor will pace up the demand of the Global Point-Of-Care Molecular Diagnostics Market.

Growing Demand for Personalized Medicine

Personalized medicine aims to customize medical care and treatment plans based on individual patient characteristics, including genetic makeup, biomarker profiles, and disease susceptibility. POC molecular diagnostics provide rapid and accurate identification of genetic variations, biomarkers, and therapeutic targets, enabling healthcare providers to tailor treatment approaches to each patient's specific needs and disease characteristics. POC molecular diagnostics enable rapid genetic testing and risk assessment for a wide range of conditions, including genetic disorders, hereditary diseases, and cancer predisposition syndromes. By detecting genetic mutations, single nucleotide polymorphisms (SNPs), and other genetic markers at the point of care, POC molecular diagnostics empower patients and healthcare providers to make informed decisions about disease prevention, screening, and management. Pharmacogenomic testing using POC molecular diagnostics helps predict individual responses to medications and optimize drug therapy regimens based on genetic factors. By identifying genetic variations that influence drug metabolism, efficacy, and toxicity, POC molecular diagnostics enable personalized prescribing practices, minimize adverse drug reactions, and enhance treatment outcomes for patients.

POC molecular diagnostics serve as companion diagnostic tests for targeted therapies and precision medicine approaches. These tests help identify patients who are most likely to benefit from specific therapies, such as targeted cancer treatments or immunotherapies, based on their molecular profiles and biomarker expression patterns. POC companion diagnostics enable timely treatment decisions, improve treatment response rates, and reduce the risk of adverse events associated with inappropriate therapy. POC molecular diagnostics facilitate real-time monitoring of disease progression, treatment response, and disease recurrence by measuring biomarker levels and genetic changes over time. By providing actionable diagnostic information at the point of care, POC molecular diagnostics support ongoing disease management strategies, enable early detection of treatment failure or disease relapse, and facilitate adjustments to treatment plans as needed. POC molecular diagnostics empower patients to take an active role in their healthcare decisions by providing access to personalized diagnostic information and treatment options. By involving patients in the decision-making process and tailoring treatment plans to their individual needs and preferences, POC molecular diagnostics enhance patient engagement, satisfaction, and adherence to therapy regimens. This factor will acceleate the demand of the Global Point-Of-Care Molecular Diagnostics Market.

Key Market Challenges

Quality Control and Assurance

POC molecular diagnostic tests are often performed in diverse settings, including clinics, physician offices, pharmacies, and remote locations with limited infrastructure. The variability in testing conditions, such as temperature, humidity, and operator skill level, can affect test performance and result accuracy. Unlike centralized laboratory testing, which is subject to stringent regulatory oversight and quality assurance protocols, POC molecular diagnostics may have less regulatory scrutiny and standardized quality control measures. This lack of uniformity in regulatory requirements and quality standards can lead to variability in test performance and result reliability across different POC testing platforms and devices. POC molecular diagnostic tests rely on high-quality sample collection and handling procedures to ensure accurate and reliable results. However, factors such as sample degradation, contamination, improper storage, and transportation can compromise sample integrity and affect test performance. Maintaining sample quality and stability is challenging in resource-limited or point-of-care settings where access to laboratory facilities and trained personnel may be limited. Developing robust molecular diagnostic assays for POC testing requires extensive optimization and validation to ensure analytical sensitivity, specificity, and reproducibility across diverse sample types and testing conditions. However, assay optimization and validation processes can be time-consuming, labor-intensive, and resource-intensive, posing challenges for manufacturers and developers of POC molecular diagnostic tests.

Infrastructure and Connectivity

POC molecular diagnostics are often deployed in settings where access to centralized laboratory facilities is limited or unavailable. This includes remote rural areas, underserved communities, and regions with inadequate healthcare infrastructure. The lack of laboratory infrastructure hinders the implementation and adoption of POC molecular diagnostic technologies. Many POC testing environments, such as clinics, field hospitals, and mobile healthcare units, operate in resource-limited settings with constrained financial, logistical, and technical resources. These settings may lack basic infrastructure such as reliable electricity, running water, and temperature-controlled storage, which are essential for performing molecular diagnostic tests safely and accurately. POC molecular diagnostic devices often require stable power sources to operate effectively. In regions with unreliable electricity grids or limited access to electricity, maintaining consistent power supply poses a significant challenge. Additionally, battery-operated devices may require frequent recharging or replacement, which can be impractical in resource-constrained settings. POC molecular diagnostic devices may rely on internet connectivity for data transmission, remote monitoring, and result reporting. However, internet infrastructure and connectivity can be unreliable or nonexistent in remote or rural areas, hindering real-time data exchange and communication between POC testing sites and healthcare facilities.

Key Market Trends

Miniaturization and Portability

Miniaturization and portability make molecular diagnostic technologies more accessible to a wider range of settings, including remote and resource-limited areas where access to centralized laboratory facilities may be limited or nonexistent. Portable POC devices can be deployed in clinics, field hospitals, community health centers, and even mobile healthcare units, bringing diagnostic testing closer to patients and improving healthcare access and equity. Miniaturized POC molecular diagnostic devices offer rapid testing capabilities, allowing for on-the-spot diagnosis and timely treatment decisions. With shorter turnaround times compared to traditional laboratory-based testing methods, portable POC devices enable healthcare providers to make real-time decisions about patient care, infection control, and public health interventions, particularly during outbreaks and emergencies. Miniaturized POC molecular diagnostic devices are designed for use at the point of care, where patients receive medical attention and treatment. These devices eliminate the need for sample transportation, centralized laboratory processing, and lengthy turnaround times associated with traditional testing methods, improving patient satisfaction, reducing healthcare costs, and enhancing overall workflow efficiency in point-of-care settings. Many miniaturized POC molecular diagnostic devices are compatible with mobile devices such as smartphones and tablets, enabling wireless connectivity, data transfer, and result reporting. Mobile integration allows healthcare providers to access and analyze diagnostic data in real time, track patient outcomes, and collaborate with colleagues remotely, enhancing clinical decision-making and care coordination.

Segmental Insights

Technology Insights

The Hybridization-Based segment is projected to experience rapid growth in the Global Point-Of-Care Molecular Diagnostics Market during the forecast period. Hybridization-based molecular diagnostic assays, such as nucleic acid hybridization and DNA microarrays, offer high sensitivity and specificity for the detection of nucleic acid targets. These assays enable the accurate identification and quantification of target sequences, making them suitable for a wide range of applications, including infectious disease diagnosis, genetic testing, and oncology. Hybridization-based assays support multiplexing, allowing simultaneous detection of multiple targets within a single reaction. This capability is particularly advantageous for diagnosing infectious diseases caused by multiple pathogens or identifying genetic mutations associated with complex diseases. Multiplex assays improve workflow efficiency, conserve sample volume, and reduce turnaround times in point-of-care settings. Hybridization-based assays are versatile and adaptable to different target molecules, including DNA, RNA, and proteins. They can be customized and optimized for specific applications and target sequences, making them suitable for diverse clinical and research purposes. Hybridization-based assays can also be integrated with various detection platforms, including microfluidic devices, biosensors, and portable instrumentation, enhancing their utility in point-of-care settings.

Application Insights

The Oncology segment is projected to experience rapid growth in the Global Point-Of-Care Molecular Diagnostics Market during the forecast period. There has been a significant rise in the incidence of cancer globally. Molecular diagnostics play a crucial role in cancer detection, prognosis, and treatment selection, which has driven the demand for point-of-care molecular diagnostic tools specifically designed for oncology applications. Timely and accurate diagnosis is critical for effective cancer treatment. Point-of-care molecular diagnostics offer the advantage of quick and precise testing at or near the patient, enabling faster diagnosis and treatment initiation. This is especially crucial in oncology, where early detection can significantly improve patient outcomes. There is a growing trend towards personalized medicine in oncology, where treatment decisions are tailored to individual patients based on their molecular profile. Point-of-care molecular diagnostics facilitate this approach by enabling real-time testing and immediate adjustment of treatment plans based on molecular findings.

Regional Insights

North America emerged as the dominant region in the Global Point-Of-Care Molecular Diagnostics Market in 2023. North America possesses advanced healthcare infrastructure, featuring well-established laboratory facilities, robust healthcare systems, and stringent regulatory frameworks. This infrastructure facilitates the development, validation, and adoption of point-of-care molecular diagnostics within the region. Renowned for its technological innovation, North America hosts numerous leading companies and research institutions actively engaged in advancing molecular diagnostic technologies. These entities drive growth in the point-of-care molecular diagnostics market by pioneering breakthroughs in molecular biology, microfluidics, and sensor technologies. North America serves as a focal point for significant investments in research and development (R&D) for healthcare technologies, particularly point-of-care molecular diagnostics. Funding from diverse sources, including government agencies, private investors, and venture capital firms, propels innovation and expedites the commercialization of new diagnostic products and platforms.

Key Market Players

Siemens Healthineers AG

Quidel Corporation

F. Hoffman-La Roche Ltd.

Danaher Corporation

Beckton & Dickinson Company

Trinity Biotech plc

Thermo Fisher Scientific Inc

bioMerieux S.A.

DiaSorin S.p.A

AccuBioTech Co., Ltd.

Report Scope:

In this report, the Global Point-Of-Care Molecular Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Point-Of-Care Molecular Diagnostics Market, By Technology:

    PCR-based Genetic Sequencing-based Hybridization-based Microarray-based

Point-Of-Care Molecular Diagnostics Market, By Application:

    Infectious Diseases Oncology Hematology Prenatal Testing Endocrinology Other

Point-Of-Care Molecular Diagnostics Market, By Test Location:

    OTC POC

Point-Of-Care Molecular Diagnostics Market, By End User:

    Decentralized Labs Hospitals Home-care Assisted Living Healthcare Facilities Others

Point-Of-Care Molecular Diagnostics Market, By Region:

    North America
    • United States
    • Canada
    • Mexico
    Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
    Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    South America
    • Brazil
    • Argentina
    • Colombia
    Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Point-Of-Care Molecular Diagnostics Market.

Available Customizations:

Global Point-Of-Care Molecular Diagnostics market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Point-Of-Care Molecular Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology (PCR-based, Genetic Sequencing-based, Hybridization-based, Microarray-based)
    • 5.2.2. By Application (Infectious Diseases, Oncology, Hematology, Prenatal Testing, Endocrinology, Other)
    • 5.2.3. By Test Location (OTC, POC)
    • 5.2.4. By End User (Decentralized Labs, Hospitals, Home-care, Assisted Living Healthcare Facilities, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2023)
  • 5.3. Market Map

6. North America Point-Of-Care Molecular Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By Application
    • 6.2.3. By Test Location
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Point-Of-Care Molecular Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Technology
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Test Location
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Point-Of-Care Molecular Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Technology
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Test Location
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Point-Of-Care Molecular Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Technology
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Test Location
        • 6.3.3.2.4. By End User

7. Europe Point-Of-Care Molecular Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By Application
    • 7.2.3. By Test Location
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Point-Of-Care Molecular Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Technology
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Test Location
        • 7.3.1.2.4. By End User
    • 7.3.2. United Kingdom Point-Of-Care Molecular Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Technology
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Test Location
        • 7.3.2.2.4. By End User
    • 7.3.3. Italy Point-Of-Care Molecular Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Technology
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Test Location
        • 7.3.3.2.4. By End User
    • 7.3.4. France Point-Of-Care Molecular Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Technology
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By Test Location
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Point-Of-Care Molecular Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Technology
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By Test Location
        • 7.3.5.2.4. By End User

8. Asia-Pacific Point-Of-Care Molecular Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By Application
    • 8.2.3. By Test Location
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Point-Of-Care Molecular Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Technology
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Test Location
        • 8.3.1.2.4. By End User
    • 8.3.2. India Point-Of-Care Molecular Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Technology
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Test Location
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Point-Of-Care Molecular Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Technology
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Test Location
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Point-Of-Care Molecular Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Technology
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By Test Location
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Point-Of-Care Molecular Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Technology
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By Test Location
        • 8.3.5.2.4. By End User

9. South America Point-Of-Care Molecular Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By Application
    • 9.2.3. By Test Location
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Point-Of-Care Molecular Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Technology
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Test Location
        • 9.3.1.2.4. By End User
    • 9.3.2. Argentina Point-Of-Care Molecular Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Technology
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Test Location
        • 9.3.2.2.4. By End User
    • 9.3.3. Colombia Point-Of-Care Molecular Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Technology
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Test Location
        • 9.3.3.2.4. By End User

10. Middle East and Africa Point-Of-Care Molecular Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Technology
    • 10.2.2. By Application
    • 10.2.3. By Test Location
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Point-Of-Care Molecular Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Technology
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By Test Location
        • 10.3.1.2.4. By End User
    • 10.3.2. Saudi Arabia Point-Of-Care Molecular Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Technology
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By Test Location
        • 10.3.2.2.4. By End User
    • 10.3.3. UAE Point-Of-Care Molecular Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Technology
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By Test Location
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Point-Of-Care Molecular Diagnostics Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Siemens Healthineers AG
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Product & Service Offerings
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel
    • 14.1.7. SWOT Analysis
  • 14.2. Quidel Corporation
  • 14.3. F. Hoffman-La Roche Ltd.
  • 14.4. Danaher Corporation
  • 14.5. Beckton & Dickinson Company
  • 14.6. Trinity Biotech plc
  • 14.7. Thermo Fisher Scientific Inc
  • 14.8. bioMerieux S.A.
  • 14.9. DiaSorin S.p.A
  • 14.10.AccuBioTech Co., Ltd

15. Strategic Recommendations

16. About Us & Disclaimer